ALAMEDA, Calif., June  25, 2026  (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (&#34;Vivani&#34; or the &#34;Company&#34;), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting

VANI

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Vivani gains Australian approval to begin SLIM-1 GLP-1 implant trial

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ALAMEDA, Calif., June  25, 2026  (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (&amp;#34;Vivani&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Vivani Medical announced Bellberry approval to initiate SLIM-1, a Phase 1 trial of NPM-139 semaglutide implant in Australia, with mid-2026 initiation expected. This follows the 2025 NPM-119 exenatide implant study and sets the stage for SLIM-2 if SLIM-1 shows favorable signals, potentially accelerating the GLP-1 implant program and expanding addressable obesity therapies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>HREC Bellberry approves SLIM-1 Phase 1 for NPM-139 semaglutide implant.</li><li>Initiation targeted for mid-2026; builds on 2025 NPM-119 exenatide implant results.</li><li>SLIM-1 is open-label, randomized, active comparator-controlled; n=20 total (10 per group).</li><li>SLIM-2 may follow if SLIM-1 is favorable, focusing on dose-ranging efficacy.</li><li>Vivani touts demand for miniature, reversible GLP-1 implants.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Vivani Medical, Inc. (VANI)</strong>: Initiates SLIM-1 in Australia; potential near-term clinical catalyst for stock.</li><li><strong>Wegovy / Novo Nordisk (NVO)</strong>: Comparator in SLIM-1; broader GLP-1 franchise dynamics could influence VANI sentiment.</li><li><strong>Novo Nordisk A/S (NVO)</strong>: Owner of Wegovy; GLP-1 therapy landscape may affect competitive positioning.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: a clinical trial initiation update with potential near-term impact on sentiment and valuation if readouts trend positive.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>HREC approval acts as a near-term positive catalyst for VANI.</li><li>Mid-2026 initiation creates a concrete clinical milestone to watch.</li><li>SLIM-2 contingent on SLIM-1 results may extend the development timeline.</li><li>GLP-1 implant platform competition and regulatory risk remain.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Vivani Medical, Inc. (NASDAQ: VANI) announced June 25, 2026.</li><li>Bellberry HREC approved SLIM-1 for NPM-139 in Australia.</li><li>SLIM-1: Phase 1, open-label, randomized, active comparator-controlled; n=10 per group.</li><li>Comparator: Wegovy (0.25 mg/week); trial duration four weeks.</li><li>NPM-139 is a semaglutide NanoPortal implant; SLIM-1 assesses safety, tolerability, PK, weight loss.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Positive SLIM-1 progress could lift VANI shares in the near term toward mid-2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>ALAMEDA, Calif., June  25, 2026  (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/VANI">VANI</a>) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has received approval from Bellberry, a human research ethics committee (HREC) in Australia to initiate SLIM-1&#x2122;, a Phase 1 clinical trial of NPM-139, a semaglutide implant.</p>  <p>Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager to conduct this Phase 1 clinical trial of NPM-139, a semaglutide implant, building on the success of the Phase 1 clinical trial with NPM-119 (exenatide implant) we conducted in Australia in 2025."</p>  <p>Dr. Mendelsohn continued: "In parallel with the execution of SLIM-1, our team is preparing diligently for SLIM-2 which, pending successful results from SLIM-1, we anticipate will be a dose-ranging efficacy-oriented trial of NPM-139 with the aim of accelerating the development of NPM-139’s clinical program. We believe that the market demand for a miniature, reversible GLP-1 implant technology will be strong, and we are fully committed to bringing this important technology to patients. We are grateful for the regulatory approval to initiate SLIM-1 and we look forward to providing further SLIM-1 updates as we proceed."</p>  <p><strong>About SLIM-1</strong></p>  <p>SLIM-1 (Semaglutide ultra Long-acting IMplant in obesity) is a Phase 1 open label, randomized, active comparator-controlled clinical trial evaluating a low-dose NPM-139 (semaglutide NanoPortal implant) and Wegovy (0.25 mg/week) over a four-week duration in obese or overweight subjects (n=10 per group). The trial will primarily assess the safety, tolerability, and pharmacokinetics of NPM-139. Weight loss will be measured.</p>  <p><strong>About Vivani Medical, Inc.</strong></p>  <p>Leveraging its proprietary NanoPortal&#x2122; platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: https://vivani.com.</p>  <p><strong>Forward-Looking Statements</strong></p>  <p>This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that are used in this press release, including express or implied statements regarding the SLIM-1 trial, including initiation, enrollment and read out dates; Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, the risks associated with developing biopharmaceutical implants and conducting clinical trials; the risk that observations in preclinical studies will not be replicated in human trials; risks associated with obtaining regulatory approvals; risks of unexpected costs or delays and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that Vivani considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in Vivani’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 13, 2026, as may be supplemented by additional filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available and speak only as of the date on which it is made. Vivani undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.</p>  <p>Company Contact:<br></br>Donald Dwyer <br></br>Chief Business Officer <br></br>info@vivani.com <br></br>(415) 506-8462</p>  <p>Investor and Media Relations Contact: <br></br>Jami Taylor <br></br>Investor and Media Relations Advisor <br></br>investors@vivani.com <br></br>(415) 506-8462</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MjQ2OCM3Njc3OTk3IzIyOTkzOTA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTM4MDJlYmMtNzZmZS00ZDU4LWEwZGMtMGI0ZTcxNTlkMzIyLTEzMTA5NDAtMjAyNi0wNi0yNS1lbg==/tiny/Vivani-Medical-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c63d8439-dc26-4ef7-af2c-4ec0db8feb4b"><img src="https://ml.globenewswire.com/media/c63d8439-dc26-4ef7-af2c-4ec0db8feb4b/small/vivani-medical-600-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Vivani Medical announced Bellberry approval to initiate SLIM-1, a Phase 1 trial of NPM-139 semaglutide implant in Australia, with mid-2026 initiation expected. This follows the 2025 NPM-119 exenatide implant study and sets the stage for SLIM-2 if SLIM-1 shows favorable signals, potentially accelerating the GLP-1 implant program and expanding addressable obesity therapies.

vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-1-clinical-trial-of-npm-139-semaglutide-implant-in-obesity-and-chronic-weight-management

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News